Hemolysis Analysis for Medical Devices: Standards, Methods, and Acceptance Criteria

Hemolysis analysis is a fundamental biocompatibility test that measures the extent to which blood-contacting medical devices damage red blood cells and release free hemoglobin into plasma. Performed in accordance with ISO 10993-4 and ASTM F756, hemolysis testing is required for regulatory submissions covering intravascular, cardiovascular, and extracorporeal devices in major markets worldwide. This article explains the technical principles, sample requirements, test methods, calculation formulas, and acceptance criteria used in professional medical device hemolysis evaluation.

Technical Overview

Hemolysis refers to the rupture of red blood cell (erythrocyte) membranes and the subsequent release of hemoglobin into the surrounding plasma or test medium. Medical devices that come into direct or indirect contact with circulating blood can induce hemolysis through two principal mechanisms: mechanical injury caused by shear stress, turbulence, or surface abrasion, and chemical injury caused by leachable substances extracted from device materials. Because free hemoglobin is nephrotoxic and can trigger oxidative tissue damage and vasoconstriction, controlling the hemolytic potential of blood-contacting devices is a patient-safety priority.

Within the hemocompatibility framework of ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), hemolysis testing falls under the hematology category of blood-device interaction assessment. The analytical principle is straightforward: fresh anticoagulated blood (human or animal origin) is exposed to the test sample or its extract under controlled conditions, the red cells are removed by centrifugation, and the concentration of free hemoglobin in the supernatant is quantified spectrophotometrically, typically at 540 nm using the cyanmethemoglobin (Drabkin's reagent) method.

The results are expressed as a hemolysis ratio (hemolysis rate), calculated against a negative control (buffer or saline) and a total-hemolysis positive control (deionized water or a detergent solution). Key standards governing this evaluation include ISO 10993-4, ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials), GB/T 16886.4 (the Chinese adoption of ISO 10993-4), and GB/T 14233.2 for infusion, transfusion, and injection equipment.

Testing Samples

Hemolysis analysis applies to any device or material intended for blood contact, whether the contact is transient, prolonged, permanent, or external communicating. Typical sample categories submitted to accredited third-party laboratories include:

Intravascular and External Communicating Devices

Peripheral and central venous catheters, intravenous cannulas, infusion sets, transfusion sets, stopcocks, needles, syringes, and hemodialyzers. These devices contact circulating blood for periods ranging from seconds to days and are the most frequent candidates for hemolysis evaluation.

Cardiovascular Implants

Coronary and peripheral stents, heart valve prostheses, vascular grafts, stent grafts, vena cava filters, pacemaker and defibrillator leads, and septal occluders. For permanently implanted devices, hemolysis data complement thrombosis and coagulation testing within a full ISO 10993-4 hemocompatibility panel.

Extracorporeal Circulation and Blood Handling Components

Blood pumps, oxygenators, cardiotomy reservoirs, extracorporeal tubing sets, blood bags, leukocyte depletion filters, apheresis columns, and cell salvage consumables, where sustained mechanical shear makes hemolytic performance a core design requirement.

Materials, Coatings, and Extracts

Raw polymers, metal alloys, surface coatings, drug-eluting matrices, adhesives, and process residues evaluated during material screening and design optimization, generally tested as extracts prepared according to ISO 10993-12.

Testing Items

A complete hemolysis evaluation typically encompasses the following test items:

• Indirect (extract) hemolysis test — evaluation of leachable-mediated red blood cell damage using material extracts.
• Direct contact hemolysis test — evaluation of surface- and mechanical-mediated damage with the intact device in contact with diluted blood.
• Hemolysis ratio (hemolysis rate) determination — the quantitative endpoint used for regulatory decisions.
• Plasma free hemoglobin concentration — absolute quantification of released hemoglobin.
• Complementary hemocompatibility endpoints where indicated — thrombosis, coagulation, platelet function, leukocyte, and complement activation per ISO 10993-4 category selection.
• Control verification — performance of negative controls (phosphate-buffered saline) and positive controls (deionized water or Triton-type detergent) to confirm assay validity.

Testing Methods

Extract (Indirect) Method

Test samples are extracted in phosphate-buffered saline or a physiological extraction vehicle following ISO 10993-12. Common extraction conditions include 37 °C for 24 hours for devices contacting blood at body temperature, with elevated-temperature conditions (for example, 50 °C for 72 hours) used when justified. Standard extraction ratios are 0.2 g of material per milliliter for irregular solids or 6 cm² of surface area per milliliter, scaled appropriately for the clinical exposure of the finished device.

Direct Contact Method

The intact test article is placed in direct contact with freshly drawn, anticoagulated, diluted blood (commonly of human or rabbit origin). The mixture is incubated at 37 °C for a standardized period, typically one to three hours, with or without defined agitation to simulate dynamic flow conditions. This method is particularly relevant for catheters, tubing, and pump components where physical geometry drives hemolytic behavior.

Spectrophotometric Quantification

Following incubation, samples are centrifuged to pellet intact erythrocytes. Drabkin's reagent is added to the supernatant to convert free hemoglobin to stable cyanmethemoglobin, and absorbance is measured at 540 nm against a reagent blank. Concentrations are determined from a calibration curve prepared with certified hemoglobin standards.

Calculation and Acceptance Criteria

The hemolysis ratio is calculated as: Hemolysis ratio (%) = (A_sample − A_negative control) / (A_total hemolysis − A_negative control) × 100, where total hemolysis is induced by deionized water or detergent. Widely applied acceptance criteria classify devices with a hemolysis ratio below 5% as essentially non-hemolytic and acceptable for most blood-contacting applications. ASTM F756 provides a graded interpretation: 0–2% nonhemolytic, 2–5% slightly hemolytic, and above 5% hemolytic. Regulatory authorities in China, the United States, and the European Union generally expect the hemolysis ratio to meet or fall below the 5% threshold, supported by valid controls.

Applications

Hemolysis analysis serves multiple purposes across the medical device product lifecycle:

• Regulatory registration submissions, including NMPA device registration in China, FDA 510(k) and PMA submissions in the United States, and CE marking technical documentation under the EU MDR.
• Biocompatibility risk assessment within ISO 10993-1 evaluation plans for all blood-contacting devices.
• Material selection and comparative screening during research and development of polymers, metals, coatings, and antithrombotic surface treatments.
• Design verification for blood pumps, oxygenators, and extracorporeal circuits, where hydrodynamic optimization directly reduces shear-induced hemolysis.
• Change control and equivalence evaluation following material substitution, supplier change, sterilization method modification, or manufacturing process adjustment.
• Lot release testing and routine quality control for infusion, transfusion, and dialysis consumables in accordance with product-specific standards such as GB/T 14233.2.

FAQ

What is medical device hemolysis analysis?

It is a quantitative in vitro biocompatibility test that measures the degree of red blood cell destruction caused by a medical device or its material extracts, expressed as a hemolysis percentage relative to negative and positive controls.

Which standards govern hemolysis testing?

The principal standards are ISO 10993-4 (and its Chinese equivalent GB/T 16886.4) for test selection and interpretation, ASTM F756 for material hemolytic properties, ISO 10993-12 for sample preparation and extraction, and GB/T 14233.2 for infusion and transfusion equipment test methods.

What is the acceptance criterion for the hemolysis ratio?

A hemolysis ratio of 5% or less is generally accepted as non-hemolytic for regulatory purposes; ASTM F756 further distinguishes nonhemolytic (0–2%), slightly hemolytic (2–5%), and hemolytic (greater than 5%) classifications.

Should the direct contact or extract method be used?

The extract method evaluates chemical leachables and suits most material screenings, while the direct contact method better captures surface and mechanical effects and is preferred for catheters, cannulas, and pump components. Many submissions include both to provide a complete hemocompatibility profile.

What blood source is used for the test?

Freshly drawn anticoagulated human or rabbit blood diluted with phosphate-buffered saline is typically used, in line with ASTM F756 and ISO 10993-4 laboratory practice. Ethical sourcing, donor screening, and validated anticoagulation are documented by accredited third-party laboratories.

When is hemolysis testing required?

Testing is required whenever a device contacts circulating blood, whether externally communicating (catheters, dialyzers, infusion sets), indirectly via gas exchange (oxygenators), or as an implant (stents, valves, grafts). It should be repeated when materials, suppliers, sterilization, or manufacturing processes change in a way that could affect blood compatibility.